Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation

• Post published:January 13, 2023
• Post category:Press Release

Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine

• Post published:December 1, 2022
• Post category:Press Release

Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue

• Post published:November 29, 2022
• Post category:Press Release

Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference

• Post published:October 26, 2022
• Post category:Press Release

Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study

• Post published:October 21, 2022
• Post category:Press Release

Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety Therapeutics

• Post published:October 19, 2022
• Post category:Press Release

Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia

• Post published:October 11, 2022
• Post category:Press Release

Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12

• Post published:October 6, 2022
• Post category:Press Release

Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology

• Post published:October 4, 2022
• Post category:Press Release

Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option

• Post published:October 1, 2022
• Post category:Press Release